R&D | March 10, 2026
UK pushes space-made medicines from orbit to patients with new support package
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Nadda underlined that India’s policy framework is aligned with this transformation
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Subscribe To Our Newsletter & Stay Updated
